Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) that was designed specifically for premature ejaculation. SSRIs have been shown to be effective for the treatment of PE. The downside to most SSRIs is that they must be taken daily in order to achieve the desired effect. Dapoxetine was designed to be taken on an "as needed" basis and has been shown to be effective when taken < 3 hours before sexual activity. Studies have shown that dapoxetine increases the intra-vaginal ejaculation latency time (IELT) - the time from vaginal penetration to male orgasm.
The following summary data are taken from the article Dapoxetine: a new option in the medical management of premature ejaculation McMahon, Chris G, Ther Adv Urol. 2012 October; 4(5): 233-251, where the author presents information and results of clinical trials of dapoxetine. We encourage physicians and patients to read the entire document.
The most comprehensive results from this work comes from the Phase III studies that included 6,081 subjects ranging in age from 18-82. In a double-blind study, each of roughly one-third of patients received one of the following doses: 30mg dapoxetine, 60 mg dapoxetine, or a placebo.
Inter-Vaginal Latency Time
For men with an average baseline IELT of 0.9 minutes, the average IELT improved to 3.1 minutes for a 30mg dose and 3.6 minutes for a 60 mg dose. Patients taking the placebo improved to 1.9 minutes.
% Good/Very Good Ejaculatory Control
The first of the subjective scores is the subject's feeling of having ejaculatory control. The per cent of subjects that believed that they had"good" or "very good" control is shown in this chart.
% Good/Very Good Sexual Satisfaction
This chart shows the per cent of subjects who felt that they had "good" or "very good" sexual satisfaction.
% Quite a Bit/Extreme Personal Distress
These next two charts are shown as horizontal bar charts to distinguish that positive results are lower scores. This first charts shows the per cent of subjects who described their ejaculatory-related personal distress as "quite a bit" or "extreme".
% Quite a Bit/Extreme Interpersonal Distress
This charts shows the per cent of subjects who described their ejaculatory-related interpersonal (with his partner) distress as "quite a bit" or "extreme".
The following table shows the % of subjects who experienced various adverse effects from taking dapoxetine:
Priligy is the brand name for the Johnson & Johnson's dapoxetine. In 2012, Furiex Pharmaceuticals entered into an agreement with ALZA Corp and Janssen Pharmaceutica (both part of Johnson & Johnson) whereby Furiex will obtain worldwide distribution rights of Priligy. Also in 2012, Furiex entered into a license agreement with Menarini to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Menarini is an international pharmaceutical company.